David Kirn
Jennerex Biotherapeutics (Jennerex, Inc.) · Jennerex Inc. · Jennerex Biotherapeutics
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name David Kirn as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:31 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT00629759 · A Study of Recombinant Vaccinia Virus to Evaluate the Safety and Efficacy of a Transdermal Injection Within the Tumor of Patients With Primary or Metastatic Hepatic CarcinomaJennerex Biotherapeutics · completed · Neoplasms, Liver · study director
- Ph1NCT00625456 · Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid TumorsJennerex Biotherapeutics · completed · Melanoma, Lung Cancer, Renal Cell Carcinoma · study director
- Ph2NCT00554372 · A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular CarcinomaJennerex Biotherapeutics · completed · Carcinoma, Hepatocellular · study director
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:31 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:31 UTC. The ranking covers the 200 most relevant of 35 PubMed records, and a shared surname and initials can bring in a namesake. All 35 on PubMed
- 895 citationsRCR 17.8
- Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer.Nat Med · 2013660 citationsRCR 17.7
- Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.Nature · 2011466 citationsRCR 10.9
- Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.Lancet Oncol · 2008428 citationsRCR 8.7
- A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma.Clin Cancer Res · 2003402 citationsRCR 8.3
- Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer.J Clin Oncol · 2001382 citationsRCR 7.9
- A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer.Clin Cancer Res · 2000367 citationsRCR 7.7
- 346 citationsRCR 6.9
- Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints.Cancer Res · 2002289 citationsRCR 5.6
- Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity.Gene Ther · 2001244 citationsRCR 5.1